Needham & Company
-
Needham & Company Weighs in on Brexit Biotech Impact (ACAD) (GILD0 (ICPT) (SGEN)
-
Needham & Company Remains Bullish on Cempra (CEMP) Following Meetings
-
Cempra to Present at the Needham and Company 15th Annual Healthcare Conference
-
Cempra Completes Public Offering of Common Stock
-
Cempra (CEMP) Prices 4.17M Shares at $24
-
Cempra Prices Public Offering of Common Stock
-
Pre-Open Stock Movers 08/19: (HILL) (CRBP) (ACI) (TGT) Higher; (TEDU) (CSIQ) (MNOV) Lower (more...)
-
Pre-Open Stock Movers 01/06: (NERV) (CYTR) (AOL) Higher; (CYBX) (MSTX) (INFN) Lower (more...)
-
Cempra (CEMP) PT Raised to $42 at Needham & Company Amid Positive Solithromycin Phase 3 Trial Data
-
Cempra (CEMP) PT Raised to $28 at Needham & Company Ahead of Phase 3 Results
-
Cempra (CEMP) Prices 7.25M Common Stock Offering
-
Needham & Company Reiterates a 'Buy' on Cempra, Inc. (CEMP); Comments From Conference Call
-
Needham & Company Maintains Buy on Cempra (CEMP) After Q4 Results
-
Needham & Company Starts Cempra, Inc. (CEMP) at Buy; Late-Stage Antibiotic Company
-
Cempra (CEMP) IPO Trades Higher
-
Cempra Holdings (CEMP) Files $86.5M IPO

